Capricor's Duchenne treatment fails to get FDA approval, shares sink
CAPR•The FDA declined to approve Capricor Therapeutics' experimental Duchenne treatment deramiocel, citing data integrity and protocol violations. Capricor shares fell 77% in extended trading.
1. FDA declines approval
The FDA declined to approve Capricor Therapeutics' deramiocel, which the company sought to use to preserve upper-limb function in patients with Duchenne muscular dystrophy. The agency said the treatment did not meet the study's main goals and that violations compromised the reliability of the data.
2. Dispute over trial data
The FDA cited unauthorized changes to the analysis plan, violations of rules intended to keep patients and researchers from knowing who received treatment, and other protocol violations. CEO Linda Marban criticized the decision, saying Capricor stood behind data she said had been independently validated before a July advisory committee meeting.
3. Earlier review
In July, FDA advisers voted 9-3 that evidence presented at the time did not establish deramiocel's effectiveness in Duchenne-related heart disease. Capricor submitted an amended application in August with 24-month data and additional analyses focused on upper-limb muscle function.




